Bisegliptin

DB06127InvestigationalSmall molecule

Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of...

Mechanism: Bisegliptin is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
Curator reviewed
Primary indication: Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
Formula / weight: C₁₈H₂₆FN₃O₃ · 351.422 g/mol (avg)
Code names: KRP-104

Resolves to

Compound

UNII9U5KQ79OK6CAS862501-61-9

Structure

InChIKeyAKFNKZFJBFQFAA-DIOPXHOYSA-NSMILES[H][C@@]1(F)CN(C(=O)CNC23CCC(CC2)(CC3)C(=O)OCC)[C@@]([H])(C1)C#N

Targets

P27487DPP4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

656Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bisegliptin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account